Underwater Fossils Surface to Reveal a Lost World of Archaic Humans
An artificial island of sand dredged from Indonesia's seafloor has accidentally revealed evidence of a long-lost sunken world, inhabited by early humans.
Scattered across the newly created island, scientists have uncovered more than 6,700 fossils of fish, reptiles, and mammals dredged from the deep, including the remains of two hominin skulls.
This is the first discovery of ancient human fossils between the islands of Indonesia. The bones belong to Homo erectus – the longest surviving of all our human relatives.
Until now, the only evidence of H. erectus in the region was confined to the island of Java. But as it turns out, this population was not so isolated after all.
More than 130,000 years ago, when sea levels were 100 meters (328 feet) lower than today, it seems that H. erectus left the island of Java and lived among the valleys and plains of sunken 'Sundaland'.
Sunda is the name for the largest drowned shelf in the world, and while it is now a shallow sea, in the past, it was occasionally a land bridge between the Asian mainland and the islands of Borneo, Sumatra, and Java.
This means that H. erectus may have even come into contact with other human species living in Asia at the time, like Neanderthals or Denisovans.
"Homo erectus could disperse from the Asian mainland to Java," says lead author and archaeologist Harry Berghuis from Leiden University in the Netherlands.
"This makes our discoveries truly unique. The fossils come from a drowned river valley, which filled up over time with river sand. We have been able to date the material to approximately 140,000 years ago."
At that time, experts suspect Sundaland resembled the African savannah. The fossils found on the artificial island included hippos, crocodiles, elephants, Komodo dragons, rhinos, big cats, and hoofed, ruminant animals, similar to bison or buffalo. Most are now extinct.
Given the dry habitat of this prehistoric ecosystem, it is likely that H. erectus stuck to the rivers in Sundaland, which would have provided a perennial source of drinking water and fish. Experts suspect the hominin may have also taken advantage of large game that visited the waters.
"Among our new finds are cut marks on the bones of water turtles and large numbers of broken bovid bones, which point to hunting and consumption of bone marrow," says Berghuis.
"We didn't find this in the earlier Homo erectus population on Java, but do know it from more modern human species of the Asian mainland. Homo erectus may have copied this practice from these populations. This suggests there may have been contact between these hominin groups, or even genetic exchange."
That's an interesting hypothesis, but further evidence is necessary.
Past fossil finds on Java have led scientists to believe this island was the last stronghold for H. erectus – a hominin that journeyed out of Africa and across Asia in a decidedly impressive two-million-year run. By 400,000 years ago, however, H. erectus had gone extinct in Asia and Africa. Yet the species persisted on Java until around 108,000 years ago.
It's a big win pulling the remains of H. erectus from the seabed off the coast of Java, but the fossils were found between a small and narrow strait separating two islands.
How much further afield H. erectus travelled from Java is a mystery.
"The answers may very well be at the bottom of the sea," write the authors.
The research was published in four installments in Quaternary Environments and Humans here, here, here, and here.
Scientists Discovered a Hidden Clue Why Men Are Taller Than Women
Being Bored Could Actually Be Good For Your Brain, Scientists Reveal
Couples Who Cuddle at Bedtime Have Lower Stress And Feel More Secure
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 hours ago
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Time Business News
19 hours ago
- Time Business News
Coating Additives – Enhancing Performance, Sustainability, and Innovation
Coating additives are specialized chemical substances used in small quantities to improve the performance and functionality of paints, coatings, and inks. These additives enhance properties such as dispersion, wetting, defoaming, leveling, adhesion, UV resistance, and durability. They play a crucial role in optimizing coating formulations for various surfaces and end-use applications, making them indispensable in industries such as automotive, construction, packaging, and electronics. In recent years, the coating additives sector has experienced significant growth, driven by increasing demand for high-performance, sustainable, and eco-friendly coating solutions. These additives are widely used in decorative and industrial coatings, printing inks, and adhesives. The surge in construction, automotive refinishing, and digital printing applications has contributed to this upward trajectory. Furthermore, the shift toward waterborne and low-VOC formulations continues to open new avenues for innovation and adoption of advanced additives. Evonik Coating Additives: Driving Innovation and Sustainability in 2025 New AERODISP Dispersions for Digital Printing In 2025, Evonik Coating Additives launched four new AERODISP dispersions based on silica (SiO₂) and alumina (Al₂O₃) particles aimed at enhancing waterborne inkjet ink receptive coatings. These dispersions offer excellent dot sharpness and high resolution, critical to the transition from analog to digital printing. By improving ink fixation and spreading behavior on substrates, they elevate the quality of digital prints. This innovation is expected to accelerate the adoption of digital printing technologies, especially in packaging and publishing, boosting demand for performance additives tailored for inkjet formulations. Introduction of Mass Balanced Additives with Reduced Carbon Footprint Evonik introduced TEGO Wet 270 eCO and TEGO Foamex 812 eCO, its first mass-balanced wetting agent and defoamer with a significantly reduced carbon footprint. Produced using ISCC-certified raw materials, these sustainable products deliver the same high-performance standards as their conventional counterparts while supporting global sustainability goals. This move positions Evonik as a leader in green chemistry and is likely to influence more coating manufacturers to adopt carbon-conscious formulations, expanding the market for eco-friendly coating additives. Strategic Partnership with Nippon Paint China Evonik's collaboration with Nippon Paint China marks a strategic milestone aimed at co-developing next-generation coating solutions. This partnership combines Evonik's advanced additive technologies with Nippon's market leadership in Asia. The joint focus on sustainability and performance is expected to yield innovative products that meet evolving regulatory standards and consumer preferences for environmentally responsible coatings. This alliance will likely set new benchmarks in the Asian coating sector, reinforcing Evonik's footprint and elevating competition through innovation. Future Outlook The future of the coating additives industry is poised for robust expansion, fueled by innovation, environmental regulations, and evolving customer demands. With rising investments in R&D and a strong focus on sustainability, the sector is expected to witness the introduction of smarter, multifunctional, and greener additives. Strategic collaborations, like that of Evonik and Nippon Paint, will further shape the global landscape, driving breakthroughs in formulation science and application performance. As digital printing, energy-efficient buildings, and electric vehicles gain traction, the demand for advanced coating additives will continue to surge across regions and industries. About the Author: HTF Market Intelligence is a leading market research company providing end-to-end syndicated and custom market reports, consulting services, and insightful information across the globe. With over 15,000+ reports from 27 industries covering 60+ geographies, value research report, opportunities, and cope with the most critical business challenges, and transform businesses. Analysts at HTF MI focus on comprehending the unique needs of each client to deliver insights that are most suited to their particular requirements. TIME BUSINESS NEWS